Home Blog of Signal Transduction Metabolism Retinoid Receptor 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group

The Childrens Cancer Study Group evaluated daily oral 13-cis-retinoic acid to determine its therapeutic efficacy in 28 children with advanced neuroblastoma refractory to conventional therapy. Cheilitis and fissured lips were the most common side effects; however, fewer than 50% of the patients experienced any toxicity. Two of twenty-two evaluable children demonstrated positive response to therapy. In one case, a child received the drug for 11 months. Seventeen patients demonstrated progressive disease within 28 days of the start of treatment. Three other patients with stable disease, or removed from study at day 28, were considered nonresponsive. Our data demonstrate that, when given as a single daily oral dose of 100 mg/m2, 13-cis-retinoic acid does not have significant activity in children with advanced neuroblastoma.

 

Comments：

This passage is discussing the results of a study conducted by the Children's Cancer Study Group on the use of 13-cis-retinoic acid in children with advanced neuroblastoma, a type of cancer that affects the nervous system. The study found that the drug, when given as a daily dose of 100 mg/m2, did not show significant activity in treating this condition. The most common side effects were cheilitis and fissured lips, but fewer than 50% of the patients experienced any toxicity. Two of the 22 evaluable children showed positive response to the therapy, but 17 patients showed progressive disease within 28 days of the start of treatment. The results of the study suggest that 13-cis-retinoic acid is not an effective treatment option for children with advanced neuroblastoma.

 

Related Products

Cat.No. Product Name Information
S1653 Retinoic acid (Tretinoin) Retinoic acid (Tretinoin), which is a ligand for both the retinoic acid receptor (RAR) and the retinoid X receptor (RXR), can induce granulocytic differentiation and apoptosis in acute promyelocytic leukemia (APL) cells. Tretinoin (NSC 122758) can be used to induce animal models of osteoporosis.

Related Targets

Retinoid Receptor